TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
23
10
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Objective: The objective of this study was to provide an in-depth analysis of the advantages and potential research directions concerning the utilization of terlipressin (TP) in combination with norepinephrine (NE) for the management of septic shock. Methods: A systematic search was conducted across five major electronic databases, namely, PubMed, Cochrane, Embase, ScienceDirect, and MEDLINE, using the Boolean method. The search encompassed articles published until May 22, 2023. Randomized controlled trials investigating the efficacy of TP combined with NE in the treatment of patients with septic shock were considered for inclusion. Results: A total of seven trials met the inclusion criteria. The combination therapy of TP and NE exhibited potential benefits in the treatment of adult patients suffering from septic shock. Furthermore, the concurrent administration of TP with NE demonstrated improvements in cardiac output and central venous pressure. However, it is important to acknowledge the presence of certain risks and potential adverse events, including an elevated risk of peripheral ischemia. Conclusions: The available evidence supports the notion that early combination therapy involving NE and TP holds promise in terms of reducing the required dosage of NE, enhancing renal perfusion, and improving microcirculation in patients diagnosed with septic shock.
Identifiants
pubmed: 37548701
doi: 10.1097/SHK.0000000000002204
pii: 00024382-202310000-00001
doi:
Substances chimiques
Norepinephrine
X4W3ENH1CV
Terlipressin
7Z5X49W53P
Lypressin
50-57-7
Vasoconstrictor Agents
0
Types de publication
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
479-486Informations de copyright
Copyright © 2023 by the Shock Society.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Bauer M, Gerlach H, Vogelmann T, et al. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019—results from a systematic review and meta-analysis. Crit Care . 2020;24(1):239.
Pepper DJ, Sun J, Welsh J, et al. Increased body mass index and adjusted mortality in ICU patients with sepsis or septic shock: a systematic review and meta-analysis. Crit Care . 2016;20(1):181.
Vincent JL, Jones G, David S, et al. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care . 2019;23(1):196.
Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med . 2020;46(8):1552–1562.
Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med . 2021;49(11):e1063–e1143.
Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev . 2019;10(10):ED000142.
Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med . 2009;6(7):e1000097.
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ . 2011;343:d5928.
Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care . 2009;13(4):R130.
Rehberg S, Ertmer C, Köhler G, et al. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Article. Intensive Care Med . 2009;35(7):1286–1296.
Xiao X, Zhang J, Wang Y, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res . 2016;200(1):274–282.
Zhi C, Ping Z, Yuanhua L, Chunli Y. Comparison of effect of norepinephrine and terlipressin on patients with ARDS combined with septic shock: a prospective single-blind randomized controlled trial. Randomized Controlled Trial . 2017;29(2):111–116.
Sahoo P, Kothari N, Goyal S, Sharma A, Bhatia PK. Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: a randomized control study. Indian J Crit Care Med . 2022;26(6):669–675.
Wang J, Shi M, Huang L, et al. Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study. Ren Fail . 2022;44(1):1207–1215.
Favory R, Salgado DR, Vincent JL. Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs . 2009;18(8):1119–1131.
Russell JA, Gordon AC, Williams MD, et al. Vasopressor therapy in the intensive care unit. Semin Respir Crit Care Med . 2021;42(1):59–77.
Yoshimura M, Conway-Campbell B, Ueta Y. Arginine vasopressin: direct and indirect action on metabolism. Peptides . 2021;142:170555.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA . 2016;315(8):801–810.
Fine J. Septic shock. JAMA . 1964;188:427–432.
Hurley JC. The role of endotoxin in septic shock. JAMA . 2019;321(9):902–903.
Zeballos G, López-Herce J, Fernández C, et al. Rescue therapy with terlipressin by continuous infusion in a child with catecholamine-resistant septic shock. Resuscitation . 2006;68(1):151–153.
Xiao X, Zhu Y, Zhen D, et al. Beneficial and side effects of arginine vasopressin and terlipressin for septic shock. J Surg Res . 2015;195(2):568–579.
López-Bojórquez LN, Dehesa AZ, Reyes-Terán G. Molecular mechanisms involved in the pathogenesis of septic shock. Arch Med Res . 2004;35(6):465–479.
Etomi R, Khan A, Prabhahar T. Is there a role for early administration of fixed low dose terlipressin in adult septic shock? Conference Abstract. Intens Care Med Exp . 2018;6. doi:10.1186/s40635-018-0201-6.
doi: 10.1186/s40635-018-0201-6
Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: The DOBUPRESS study. Article. Br J Anaesth . 2008;100(4):494–503.
Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med . 2018;44(11):1816–1825.
Zhu Y, Huang H, Xi X, et al. Terlipressin for septic shock patients: a meta-analysis of randomized controlled study. J Intensive Care . 2019;7:16.
Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int . 2017;37(4):552–561.
Seheult J, Fitzpatrick G, Boran G. Lactic acidosis: an update. Clin Chem Lab Med . 2017;55(3):322–333.
Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA . 2019;321(7):654–664.
Chapleau MW, Hajduczok G, Sharma RV, et al. Mechanisms of baroreceptor activation. Clin Exp Hypertens . 1995;17(1–2):1–13.
von Euler US. Physiologic basis for the clinical use of noradrenalin. Ann Intern Med . 1954;41(4):699–708.
Moreau R, Barrière E, Tazi KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. Hepatology . 2002;36(5):1070–1078.
Yamamoto K, Ikeda U, Okada K, et al. Arginine vasopressin inhibits nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Hypertens Res . 1997;20(3):209–216.
Domizi R, Calcinaro S, Harris S, et al. Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation. J Crit Care . 2020;57:185–190.
Schupp T, Weidner K, Rusnak J, et al. Norepinephrine dose, lactate or heart rate: what impacts prognosis in sepsis and septic shock? Results from a prospective, monocentric registry. Curr Med Res Opin . 2023;39(5):647–659.
Annane D, Ouanes-Besbes L, de Backer D, et al. A global perspective on vasoactive agents in shock. Intensive Care Med . 2018;44(6):833–846.
Huang L, Zhang S, Chang W, et al. Terlipressin for the treatment of septic shock in adults: a systematic review and meta-analysis. BMC Anesthesiol . 2020;20(1):58.
Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med . 2003;31(1):215–220.
Morelli A, Donati A, Ertmer C, et al. Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock. Intensive Care Med . 2011;37(6):963–969.
Qiu X, Huang Y, Xu J, et al. Effects of terlipressin on microcirculation of small bowel mesentery in rats with endotoxic shock. J Surg Res . 2014;188(2):503–509.
Schneider AG, Schelleman A, Goodwin MD, et al. Contrast-enhanced ultrasound evaluation of the renal microcirculation response to terlipressin in hepato-renal syndrome: a preliminary report. Ren Fail . 2015;37(1):175–179.
Morelli A, Donati A, Ertmer C, et al. Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock. Crit Care . 2011;15(5):R217.
Yang X, Zhou Y, Liu A, et al. Relationship between dynamic changes of microcirculation flow, tissue perfusion parameters, and lactate level and mortality of septic shock in ICU. Contrast Media Mol Imaging . 2022;2022:1192902.
Watchorn J, Huang D, Bramham K, et al. Decreased renal cortical perfusion, independent of changes in renal blood flow and sublingual microcirculatory impairment, is associated with the severity of acute kidney injury in patients with septic shock. Crit Care . 2022;26(1):261.
Thooft A, Favory R, Salgado DR, et al. Effects of changes in arterial pressure on organ perfusion during septic shock. Crit Care . 2011;15(5):R222.
Hepatobiliary Study Group of Chinese Society of Gastroenterology of Chinese Medical Association; Hepatology Committee of Chinese Research Hospital Association. Practice guidance for the use of terlipressin for liver cirrhosis-related complications (2021). Zhonghua Gan Zang Bing Za Zhi . 2022;30(8):859–865.
Taşliyurt T, Kutlutürk F, Erdemır F, et al. Ischemic skin necrosis following terlipressin therapy: report of two cases and review of the literature. Turk J Gastroenterol . 2012;23(6):788–791.
Iglesias Julián E, Badía Aranda E, Bernad Cabredo B, et al. Cutaneous necrosis secondary to terlipressin therapy. A rare but serious side effect. Case report and literature review. Rev Esp Enferm Dig . 2017;109(5):380–382.
Zhou Y, Zeng J, Song L, et al. Clinical characteristics and treatment of terlipressin-induced ischemic skin necrosis: a synthesis of 35 literature reported cases. J Clin Pharm Ther . 2022;47(8):1270–1275.
Jain G, Chandran P, Patnaik I, et al. Terlipressin-induced skin necrosis. BMJ Case Rep . 2021;14(11):e246678.